Drug intelligence / Profile preview

ABYTNFR1-1

Development stage: Unknown
Lead developer: University of Minnesota

Overview

ABYTNFR1-1: sourced facts only. name: "Using yeast display, we identified a synthetic affibody ligand (ABYTNFR1-1) with high binding affinity and specificity for TNFR1." [PMID:36897792]; target: "Using yeast display, we identified a synthetic affibody ligand (ABYTNFR1-1) with high binding affinity and specificity for TNFR1." [PMID:36897792]; developer: "Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States." [PMID:36897792]

Targets

TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)

Beyond the preview

Go deeper on ABYTNFR1-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABYTNFR1-1.